Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax, Inc. (Nasdaq: NVAX) announced its selection for Operation Warp Speed, receiving a $1.6 billion award to advance its COVID-19 vaccine, NVX-CoV2373. This funding will support late-stage clinical trials, including a pivotal Phase 3 trial with up to 30,000 subjects, and large-scale manufacturing of 100 million doses. Preliminary safety results from a Phase 1/2 trial are expected by late July 2020, with additional support from CEPI amounting to $388 million. This partnership aims to expedite vaccine delivery amid the COVID-19 pandemic.
Novavax, Inc. (NASDAQ: NVAX) announced the appointment of Frank Czworka as Senior Vice President, Global Sales, and the promotion of Brian Webb to Senior Vice President, Manufacturing. Czworka, with over 20 years of experience, has previously held senior roles in biopharmaceutical sales and marketing. Webb has been instrumental in expanding manufacturing capabilities. The company aims to advance its COVID-19 vaccine candidate, NVX-CoV2373, and its quadrivalent influenza nanoparticle vaccine, NanoFlu, to the market, intending to positively impact global health.
Novavax (NASDAQ: NVAX) announced the appointment of Ben Machielse as Executive Vice President, CMC, on June 29, 2020. Machielse will oversee manufacturing and regulatory functions as the company advances its COVID-19 vaccine candidate, NVX-CoV2373. Other leadership promotions include John Trizzino as Chief Business Officer and CFO, John Herrmann III as Chief Legal Officer, and Jill Hoyt as Chief Human Resources Officer. Novavax is ramping up its manufacturing capacity for its vaccines, which include NVX-CoV2373 and NanoFlu, with clinical trial results expected soon.
Novavax, a biotechnology company focused on vaccines, will have its Chief Business Officer, John J. Trizzino, participate in the H.C. Wainwright Virtual Fireside Chat on June 25, 2020, at 10:00 a.m. ET. The discussion will center on Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This candidate is part of Novavax's broader mission to develop innovative vaccines, including the NanoFlu™, which recently succeeded in a Phase 3 trial. More insights can be found on Novavax's website.
Novavax, Inc. (NASDAQ: NVAX) has appointed David Mott as an independent director of its Board, enhancing its leadership team with his extensive experience in biopharmaceuticals. Mott, who recently acquired nearly 65,000 shares of Novavax, brings over 30 years of management and investment expertise. His appointment comes as Novavax ramps up efforts in developing its COVID-19 vaccine (NVX-CoV2373) and prepares for regulatory submissions for NanoFlu™. Mott will also serve on the Compensation Committee, aiming to support the company's mission against serious infectious diseases.
Novavax (NASDAQ: NVAX) announced a private placement agreement to sell Series A Convertible preferred stock to RA Capital Management, converting into 4,388,852 shares of common stock at the June 12 closing price. The deal will provide Novavax with gross proceeds of approximately $200 million. This funding is expected to bolster Novavax's ongoing vaccine development efforts against COVID-19 and influenza. The preferred shares do not have voting rights and are not entitled to dividends. The transaction is part of Novavax's strategy to enhance its financial position and facilitate critical vaccine trials.
Novavax, Inc. (NASDAQ: NVAX) announced that Gregory M. Glenn, M.D., President of Research and Development, will participate in a panel discussion on COVID-19 vaccines at the 2020 BIO Digital conference on June 9 at 11:30 a.m. EDT. The panel will explore the complexities of vaccine development and the importance of collaboration in bringing vaccines to market. Additionally, Novavax is advancing its NVX-CoV2373 vaccine candidate for COVID-19 with Phase 1 results expected in July 2020, alongside positive Phase 3 results for its NanoFlu vaccine targeting influenza.
Novavax, Inc. (NASDAQ: NVAX) announced a $60 million contract with the U.S. Department of Defense (DoD) to manufacture its COVID-19 vaccine candidate, NVX-CoV2373. The funding will support the production of components required to deliver 10 million doses by the end of 2020. This contract aims to enhance Novavax's U.S. production capacity, facilitating support for the COVID-19 pandemic. The vaccine, incorporating proprietary technologies, shows promise in preclinical trials for generating antibodies to combat the virus.
Novavax (NASDAQ: NVAX) announced the enrollment of the first participants in the Phase 1/2 clinical trial for its coronavirus vaccine, NVX-CoV2373. This vaccine utilizes proprietary nanoparticle technology and Matrix-M™ adjuvant to boost immune response. Preliminary results on immunogenicity and safety are anticipated in July 2020, with the Phase 2 trial set to follow if Phase 1 results are promising. The trial is supported by funding from CEPI, highlighting Novavax's commitment to combating COVID-19.
Novavax (NASDAQ: NVAX) has secured up to $384 million in additional funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the clinical development of its coronavirus vaccine, NVX-CoV2373. This funding enhances the rapid scale-up of vaccine manufacturing and the production of Matrix-M™ adjuvant, aiming to significantly boost global vaccine supply. Key plans include initiating a Phase 1/2 clinical trial in Australia and potentially manufacturing over one billion vaccine doses in 2021, highlighting a strong commitment to global equitable access.